1. Home
  2. LNSR vs ELDN Comparison

LNSR vs ELDN Comparison

Compare LNSR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$10.27

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$1.48

Market Cap

120.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNSR
ELDN
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Electronics
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
120.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LNSR
ELDN
Price
$10.27
$1.48
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$15.00
$11.00
AVG Volume (30 Days)
75.6K
4.0M
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,141,000.00
N/A
Revenue This Year
$30.80
N/A
Revenue Next Year
$33.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.02
N/A
52 Week Low
$7.13
$1.35
52 Week High
$17.31
$5.08

Technical Indicators

Market Signals
Indicator
LNSR
ELDN
Relative Strength Index (RSI) 43.36 31.96
Support Level $9.56 $1.54
Resistance Level $10.48 $1.68
Average True Range (ATR) 0.37 0.19
MACD 0.07 -0.02
Stochastic Oscillator 74.31 22.41

Price Performance

Historical Comparison
LNSR
ELDN

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: